The global blood culture test market was valued at USD 6.71 billion in 2023 and it is predicted to surpass around USD 21.47 billion by 2033 with a CAGR of 12.34% from 2024 to 2033.
The blood culture test market plays a pivotal role in the diagnosis and management of various infectious diseases. This comprehensive overview delves into the key factors influencing the market, including current trends, growth drivers, challenges, and opportunities. Understanding the dynamics of the blood culture test market is essential for stakeholders, healthcare professionals, and investors aiming to navigate this evolving landscape.
The growth of the blood culture test market is propelled by various factors contributing to its expanding significance in the healthcare sector. Firstly, the rising global incidence of infectious diseases, particularly sepsis and hospital-acquired infections, has significantly increased the demand for accurate and timely diagnostic solutions, driving the market's expansion. Additionally, continual technological advancements play a pivotal role, with innovations such as automated blood culture systems and molecular diagnostics enhancing the efficiency and precision of diagnostic procedures. The incorporation of these advanced technologies not only reduces turnaround times but also contributes to improved patient outcomes. Moreover, the market is buoyed by the strategic initiatives of key players, who constantly strive to expand their product portfolios and geographic reach.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 12.34% |
Market Revenue by 2032 | USD 21.47 billion |
Revenue Share of North America in 2023 | 41% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The consumables segment held the largest revenue share of 60% in 2023 and is projected to experience the fastest CAGR throughout the forecast period. The dominant market position can be attributed to the increasing number of blood culture tests, a rising incidence of infectious diseases, and a growing awareness of the procedure's benefits. Technological advancements and continuous improvements in existing products are expected to create a conducive environment for the growth of this segment. For instance, in February 2022, Kurin, Inc. introduced its proprietary push-button needle system, showcasing a commitment to advanced safety measures.
Software systems have been developed to mitigate false positives during the blood culture test process, aiming to prevent incorrect diagnoses. An inaccurate diagnosis not only significantly escalates healthcare costs but may also lead to fatalities due to the administration of wrongly prescribed medications. Moreover, these software systems play a crucial role in determining the degree of relatedness between various analyzed strains, offering highly reproducible and discriminatory data.
The market is categorized based on techniques into conventional and automated segments. In 2023, the conventional blood culture technique segment contributed the largest market share of 65%. This dominance can be attributed to its widespread utilization in hospitals, pathology laboratories, and clinical laboratories. Additionally, the segment is poised for growth due to the increasing focus on research and development activities aimed at enhancing the efficiency of blood culture tests. A notable example is the collaborative research conducted by the Great Ormond Street Institute of Child Health (GOSH) and Wyss Institute for Biologically in December 2022, which reported successful results in reengineered procedures for identifying pathogens associated with pediatric sepsis.
On the other hand, the automated blood culture technique segment is expected to exhibit the fastest growth rate during the forecast period. Key companies in the market are keenly concentrating on introducing advanced instruments and consumables to offer highly efficient and reliable tests. In January 2022, QIAGEN launched the EZ2 Connect MDx platform, designed to automate sample processing in diagnostic labs, thereby enhancing overall process efficiency. This emphasis on automation aligns with the growing demand for streamlined and technologically advanced blood culture testing methods.
The culture-based technology segment had the largest market share of 68% in 2023. This dominance is attributed to the heightened capabilities of this technology in detecting pathogens effectively. The increasing prevalence of infectious diseases and rising research and development investments in developing countries are anticipated to further propel the growth of this segment. The widespread use of culture-based technology across various end-use locations, including hospitals, physician office laboratories, reference, and pathology settings, is also expected to be a driving factor for its continued growth.
In contrast, the molecular technology segment is poised to register the highest CAGR during the forecast period. Molecular technologies, encompassing blood cultures and nucleic acid amplification & probe tests, have notably enhanced the precision and speed of results, reducing turnaround times in Bloodstream Infections (BSIs). Innovative approaches for rapid BSI diagnosis, such as automated Antibiotic Susceptibility Testing (AST) from positive blood culture bottles by Accelerate Diagnostics and direct pathogen detection from peripheral blood by T2 Biosystems, boast an expected turnaround time of less than 6 hours. The approval of these tests is anticipated to yield more informative, cost-effective, and expeditious results, contributing significantly to BSI management.
The bacterial infections segment held the largest revenue share of 72% in 2023 and is projected to experience the highest CAGR throughout the forecast period. This dominance is primarily attributed to the escalating global incidence of bacterial infections. The strategic collaborations among market players aimed at introducing new products and technologies are anticipated to further accelerate the growth of this segment. A noteworthy example is the partnership forged in April 2022 between bioMerieux and Oxford Nanopore Technologies plc. This collaboration aims to develop faster, more accurate, and user-friendly blood culture tests, enhancing the diagnosis and treatment of infectious diseases.
In contrast, the fungal infections segment is poised to witness significant growth in the upcoming years. This growth is driven by the prevalence of Bloodstream Infections (BSIs) and the increasing number of sepsis cases on a global scale. Candida species, in particular, stand out as predominant agents of fungal sepsis, constituting approximately 10% to 15% of healthcare-related infections.
The hospital laboratories segment accounted for the largest share of 55% in 2023 owing to an increasing rate of hospitalizations and growing cases of Hospital-acquired Infections (HAIs). According to an article published by WHO in 2022, 7 patients and 15 patients out of every 100 patients in an acute-care hospital setting in high-income and low & middle-income countries respectively, will acquire at least one HAI at the time of their stay in hospital. Typically, in such settings, prompt detection allows the physicians to plan a proper treatment regimen for the patient. In underdeveloped and developing countries, which lack access to rapid diagnostic tests, hospitals serve as primary testing facilities.
The reference laboratory segment is anticipated to witness the fastest CAGR during the forecast period. Reference laboratories are often listed by insurance companies for specific tests, requiring patients to provide samples for testing. With an increase in incidence of infectious diseases, volume of blood culture tests has also increased causing a spur in the growth of reference laboratories segment.These laboratories operate privately and are engaged in a high volume of routine and specialty testing. These facilities have several advantages, such as they provide fast results (approximately 3–4 hours); are highly sensitive, specific, scalable, & cost-efficient; and facilitate the testing of many sample types.
North America dominated the market with the largest market share of 41% in 2023. This leadership position is attributed to a well-established clinical diagnostics industry, the presence of numerous key players, government-funded programs, a structured reimbursement framework, awareness initiatives, and frequent new product launches. Notably, in February 2022, the Biomedical Advanced Research and Development Authority (BARDA) received FDA Approval for the Selux NGP System, developed in collaboration with Selux Diagnostics, Inc. This system facilitates testing directly from positive blood cultures, effectively reducing the total test time from 36 hours to 16 hours from whole blood collection.
On the other hand, Asia Pacific is poised to witness the highest CAGR during the forecast period. This growth is driven by an increase in hospitalizations and a rise in the incidence of various diseases such as urinary tract infections, bloodstream infections, and ventilator-associated pneumonia. Key market players are strategically expanding their presence into Asian countries like China and India due to high unmet needs, abundant opportunities for market share growth, and the presence of the target population. The region's dynamic healthcare landscape and evolving market conditions contribute to the anticipated rapid growth in blood culture tests in Asia Pacific.
By Product
By Technique
By Technology
By Application
By End-use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Blood Culture Test Market
5.1. COVID-19 Landscape: Blood Culture Test Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Blood Culture Test Market, By Product
8.1. Blood Culture Test Market, by Product, 2024-2033
8.1.1. Consumables
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Software & Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Blood Culture Test Market, By Technique
9.1. Blood Culture Test Market, by Technique, 2024-2033
9.1.1. Conventional
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Automated
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Blood Culture Test Market, By Technology
10.1. Blood Culture Test Market, by Technology, 2024-2033
10.1.1. Culture-based Technology
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Molecular Technology
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. PCR
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Microarray
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. PNA-FISH
10.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Blood Culture Test Market, By Application
11.1. Blood Culture Test Market, by Application, 2024-2033
11.1.1. Bacterial Infections
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Fungal Infections
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Mycobacterial Infections
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Blood Culture Test Market, By End-use
12.1. Blood Culture Test Market, by End-use, 2024-2033
12.1.1. Hospital Laboratories
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Reference Laboratories
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Blood Culture Test Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.3. Market Revenue and Forecast, by Technology (2021-2033)
13.1.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.5. Market Revenue and Forecast, by End-use (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Technology (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.7. Market Revenue and Forecast, by End-use (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Technology (2021-2033)
13.1.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.3. Market Revenue and Forecast, by Technology (2021-2033)
13.2.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Technology (2021-2033)
13.2.7. Market Revenue and Forecast, by Application (2021-2033)
13.2.8. Market Revenue and Forecast, by End-use (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Technology (2021-2033)
13.2.10. Market Revenue and Forecast, by Application (2021-2033)
13.2.11. Market Revenue and Forecast, by End-use (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Technology (2021-2033)
13.2.12.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.13. Market Revenue and Forecast, by End-use (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Technique (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Technology (2021-2033)
13.2.14.4. Market Revenue and Forecast, by Application (2021-2033)
13.2.15. Market Revenue and Forecast, by End-use (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.3. Market Revenue and Forecast, by Technology (2021-2033)
13.3.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Technology (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.7. Market Revenue and Forecast, by End-use (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Technology (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.9. Market Revenue and Forecast, by End-use (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Technology (2021-2033)
13.3.10.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Technique (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Technology (2021-2033)
13.3.11.4. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.3. Market Revenue and Forecast, by Technology (2021-2033)
13.4.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Technology (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.7. Market Revenue and Forecast, by End-use (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Technology (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.9. Market Revenue and Forecast, by End-use (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Technology (2021-2033)
13.4.10.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Technique (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Technology (2021-2033)
13.4.11.4. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.3. Market Revenue and Forecast, by Technology (2021-2033)
13.5.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Technology (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.7. Market Revenue and Forecast, by End-use (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Technique (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Technology (2021-2033)
13.5.8.4. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.5. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 14. Company Profiles
14.1. BD
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Terumo Corporation
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bruker Corporation
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. bioMerieux
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. T2 Biosystems Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Luminex Corporation
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Abbott Laboratories
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Siemens Healthineers AG
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Danaher Corporation
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. F. Hoffmann-La Roche Ltd.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms